Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Journal of Neurology|September 20, 2005
Aggressive multiple sclerosis-is there a role for stem cell transplantation?Eva Havrdova
The New England Journal of Medicine|April 26, 2013
Oral BG-12 in multiple sclerosisRobert J Fox, Eva Havrdova
Neurological Research|August 23, 2012
Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosisVeronika Ticha, Tomas Kalincik, Eva Havrdova
Therapeutic Advances in Neurological Disorders|January 14, 2015
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useEva Havrdova, Dana Horakova, Ivana Kovarova
Neurology|April 28, 2010
Freedom from disease activity in multiple sclerosisEva Havrdova, Steven Galetta, Dusan Stefoski, et al.
Autoimmunity Reviews|April 22, 2017
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic reviewBernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, et al.
The Clinical Neuropsychologist|October 5, 2012
Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)Jana Blahova Dusankova, Tomas Kalincik, Eva Havrdova, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panelJ Theodore Phillips, Michael Hutchinson, Robert Fox, et al.
European Neurology|August 8, 2016
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)Klara Novotna, Lukas Sobisek, Dana Horakova, et al.
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Journal of Neurology|September 20, 2005
Aggressive multiple sclerosis-is there a role for stem cell transplantation?Eva Havrdova
The New England Journal of Medicine|April 26, 2013
Oral BG-12 in multiple sclerosisRobert J Fox, Eva Havrdova
Neurological Research|August 23, 2012
Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosisVeronika Ticha, Tomas Kalincik, Eva Havrdova
Therapeutic Advances in Neurological Disorders|January 14, 2015
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useEva Havrdova, Dana Horakova, Ivana Kovarova
Neurology|April 28, 2010
Freedom from disease activity in multiple sclerosisEva Havrdova, Steven Galetta, Dusan Stefoski, et al.
Autoimmunity Reviews|April 22, 2017
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic reviewBernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, et al.
The Clinical Neuropsychologist|October 5, 2012
Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)Jana Blahova Dusankova, Tomas Kalincik, Eva Havrdova, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panelJ Theodore Phillips, Michael Hutchinson, Robert Fox, et al.
European Neurology|August 8, 2016
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)Klara Novotna, Lukas Sobisek, Dana Horakova, et al.
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Pageof 13